Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Cyxone logo — Life-changing treatments for disorders of the immune system

Cyxone

Life-changing treatments for disorders of the immune system

Founded 2015 Sweden Sweden 11 employees Biotechnology, Health Care

General Information

Company Name Cyxone
Founded Year 2015
Location Sweden Sweden +1
Employees 11
Industries Biotechnology, Health Care
Social

Get notified when Cyxone moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Cyxone

Cyxone is a Swedish clinical biotech company that focuses on developing immunomodulating drugs for treating autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The company's portfolio includes rabeximod, currently in a clinical phase II program for RA, and T20K, which has completed a phase I infusion study for MS. Cyxone aims to address the unmet need for new, effective, and safe medicines to enhance the quality of life for patients with autoimmune diseases. Founded in 2015, the company operates in the biotechnology and health care industries, with its headquarters in Sweden. Despite the absence of recent disclosed investments and investors, Cyxone's focus on addressing autoimmune diseases through innovative drugs positions it as a potential opportunity for venture capital looking to invest in the biotech sector.

Taxonomy: biotech, clinical research, immunomodulating drugs, autoimmune diseases, multiple sclerosis, rheumatoid arthritis, pharmaceuticals, drug development, clinical trials, immune system disorders, medicine, quality of life, treatment, therapy, clinical phase II program

No funding data available for Cyxone yet.

Get notified when Cyxone raises funding

Cyxone Alternatives & Competitors

Cyxone vs
Cantargia AB
Cantargia AB Sweden

A Swedish listed biotechnology company

Post Ipo Equity
32 employees
Biotechnology, Health and Wellness
Cyxone vs
Ventyx Biosciences
Ventyx Biosciences United States

Ventyx Biosciences is a clinical-stage biopharmaceutical company developing innovative oral therapie...

Post Ipo Equity
242 employees
Biopharma, Biotechnology
Cyxone vs
Imcyse SA
Imcyse SA Belgium

Pioneering the development of Imotopes™ to prevent, stop and potentially cure autoimmune diseases

Series B
17 employees
Biotechnology, Health and Wellness

FAQ About Cyxone

Life-changing treatments for disorders of the immune system
Cyxone was founded in 2015.
Cyxone is headquartered in Sweden.
Cyxone operates in the following industries: Biotechnology, Health Care.
Cyxone has approximately 11 employees.
Top alternatives and competitors to Cyxone include Cantargia AB, Ventyx Biosciences, Imcyse SA, Anthera Pharmaceuticals, ImageneBio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Cyxone and Cantargia AB are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Cyxone and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy